Koji Yoshinaga Selected Research

specific substance maruyama (Z-100)

3/2015	Z-100, extracted from Mycobacterium tuberculosis strain Aoyama B, promotes TNF-α production via nucleotide-binding oligomerization domain containing 2 (Nod2)-dependent NF-κB activation in RAW264.7 cells.
1/2014	Z-100, an immunomodulatory extract of Mycobacterium tuberculosis strain Aoyama B, prevents spontaneous lymphatic metastasis of B16-BL6 melanoma.
1/2004	Z-100, an immunomodulatory arabinomannan extracted from Mycobacterium tuberculosis strain Aoyama B, augments anti-tumor activities of X-ray irradiation against B16 melanoma in association with the improvement of type 1T cell responses.
9/2003	Antimetastatic effect of an immunomodulatory arabinomannan extracted from Mycobacterium tuberculosis strain Aoyama B, Z-100, through the production of interleukin-12.
1/2002	Anti-tumor mechanism of Z-100, an immunomodulatory Arabinomannan extracted from Mycobacterium tuberculosis strain Aoyama B, on pulmonary metastases of B16F10 melanoma: restoration of helper T cell responses via suppression of glucocorticoid-genesis.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Koji Yoshinaga Research Topics

Disease

7	Neoplasms (Cancer) 03/2015 - 01/2002
5	Pancreatic Neoplasms (Pancreatic Cancer) 10/2011 - 04/2008
4	Melanoma (Melanoma, Malignant) 01/2014 - 01/2002
3	Neoplasm Metastasis (Metastasis) 01/2014 - 01/2002
2	Pain (Aches) 10/2010 - 01/2010
2	Adenocarcinoma 01/2010 - 04/2008
1	Lymphatic Metastasis 01/2014
1	Herpes Zoster 08/2013
1	Hypoxia (Hypoxemia) 10/2011
1	Carcinogenesis 10/2011
1	Dyspepsia (Indigestion) 03/2011
1	Cancer Pain 01/2010
1	Ageusia (Hypogeusia) 11/2009
1	Dysgeusia (Parageusia) 01/2006
1	Taste Disorders (Taste Disorder) 01/2006
1	Experimental Melanoma 01/2004

Drug/Important Bio-Agent (IBA)

5	specific substance maruyama (Z-100)IBA 03/2015 - 01/2002
5	Z-360IBA 10/2011 - 04/2008
4	Cholecystokinin B ReceptorIBA 10/2011 - 04/2008
4	Gemcitabine FDA Link 10/2011 - 04/2008
3	Pharmaceutical PreparationsIBA 03/2011 - 01/2010
3	Cholecystokinin (Pancreozymin)IBA 01/2010 - 04/2008
3	CytokinesIBA 01/2004 - 01/2002
2	GastrinsIBA 10/2011 - 04/2008
2	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 10/2011 - 01/2010
2	Analgesics (Analgesic Drugs)IBA 10/2010 - 01/2010
2	polaprezinc (Z 103)IBA 11/2009 - 01/2006
2	arabinomannanIBA 01/2004 - 01/2002
1	Granzymes (Granzyme)IBA 01/2014
1	Proteins (Proteins, Gene)FDA Link 01/2014
1	Peptide Hydrolases (Proteases)FDA Link 08/2013
1	TrypsinIBA 08/2013
1	ThiazolesIBA 03/2011
1	Z 338IBA 03/2011
1	Interleukin-1 (Interleukin 1)IBA 10/2010
1	Sincalide FDA Link 10/2010
1	Opioid Analgesics (Opioids)IBA 10/2010
1	Tyrosine (L-Tyrosine)FDA Link 10/2010
1	N-Methyl-D-Aspartate Receptors (NMDA Receptors)IBA 10/2010
1	DevazepideIBA 10/2010
1	Ephrin-B1 (Ephrin B1)IBA 10/2010
1	Formaldehyde (Formol)FDA Link 01/2010
1	Morphine (MS Contin)FDA LinkGeneric 01/2010
1	Cholecystokinin A ReceptorIBA 01/2010
1	CalciumIBA 04/2008
1	Benzoates (Benzoate)IBA 04/2008
1	ZincIBA 01/2006
1	InterleukinsIBA 09/2003
1	Interleukin-12 Subunit p40IBA 09/2003
1	Interleukin-10 (Interleukin 10)IBA 09/2003
1	Interleukin-12 (IL 12)IBA 09/2003
1	Cholesterol Side-Chain Cleavage Enzyme (CYP11A1)IBA 01/2002
1	CorticosteroneIBA 01/2002
1	GlucocorticoidsIBA 01/2002
1	Messenger RNA (mRNA)IBA 01/2002

Therapy/Procedure

3	Therapeutics 10/2011 - 01/2004
1	Immunotherapy 03/2015
1	Intraperitoneal Injections 10/2010
1	Oral Administration 01/2010
1	Radiotherapy 01/2004